• BioHarvest Q2 2026 revenue rose 3.8% to USD 8.8 million; IFRS net loss narrowed to USD 3.7 million, or USD 0.17 per share.
• IFRS operating loss widened to USD 2.5 million; gross margin slipped 1 percentage point to 58%.
• Non-IFRS adjusted EBITDA loss widened to USD 1.6 million, including USD 0.9 million in CDMO services.
• Secured its first CDMO manufacturing and supply agreement backing a planned 20-ton fragrance program over two years; limited production could start in H1 2027.
• Cut full-year CDMO revenue outlook to USD 4-5 million; lowered expected CDMO EBITDA loss to USD 1.5-2.5 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioharvest Sciences Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608110630NEWSFILECNPR____20260811_309164_1) on August 11, 2026, and is solely responsible for the information contained therein.